Oncocyte first to published randomized interventional data to rule-in for biopsy in high-risk patient population Study shows that monitoring with ...

One of the major stories in multiple myeloma in 2024 was the comeback of belantamab mafodotin (Blenrep) after it had been ...

Johnson & Johnson (J&J) has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies ...